Trials / Conditions / Neoadjuvant Chemoimmunotherapy

Neoadjuvant Chemoimmunotherapy

18 registered clinical trials studyying Neoadjuvant Chemoimmunotherapy — 15 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Simplified Exercise-based Risk Assessment in Lung Cancer NCT07506889	Linkoeping University	—
Recruiting	Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC NCT07528066	Shanghai Chest Hospital	—
Not Yet Recruiting	Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcin NCT07145931	Sun Yat-sen University	Phase 2
Recruiting	Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer NCT07478900	All India Institute of Medical Sciences, Bhubaneswar	N/A
Not Yet Recruiting	Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advance NCT07137858	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Phase 2
Not Yet Recruiting	Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junct NCT07092449	Tang-Du Hospital	N/A
Recruiting	Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and NCT07165847	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Phase 2
Recruiting	NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (N NCT07121374	University Hospital, Antwerp	Phase 1 / Phase 2
Recruiting	Neoadjuvant Immunochemotherapy in PD-L1-negative LACC NCT06288360	Tongji Hospital	Phase 2
Recruiting	Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer NCT06289751	Tongji Hospital	Phase 2
Recruiting	Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer NCT06289062	Tongji Hospital	Phase 2
Recruiting	Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC NCT06288373	Tongji Hospital	Phase 2 / Phase 3
Unknown	Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemoth NCT06285058	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	—
Recruiting	Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell NCT06436040	Tang-Du Hospital	—
Recruiting	Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma NCT06056336	Guo Xufeng	Phase 2
Unknown	Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non NCT05925751	Shanghai Pulmonary Hospital, Shanghai, China	—
Active Not Recruiting	Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatmen NCT07127497	The First Affiliated Hospital of Anhui Medical University	Phase 2
Recruiting	Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT05740995	Shanghai Zhongshan Hospital	—